The clinical problem is enormous. Diabetic neuropathy encompasses a heterogeneous set of conditions: loss of sensation in the feet, burning neuropathic pain, dysfunction of the autonomic nerves that regulate the heart and gut, and the slow degeneration of the long axons that connect the spinal cord to the toes. High blood glucose alone cannot fully explain this spectrum. What unites these presentations, the authors contend, is the extraordinary bioenergetic demand of peripheral nerves. Long axons, the Schwann cells that insulate them, and autonomic neurons all depend on a continuous supply of ATP generated by oxidative phosphorylation. When mitochondria falter, these cells are among the first to suffer, which is precisely why the longest nerve fibers—those serving the feet—degenerate first.

At the biochemical level, the review describes how hyperglycaemia, lipotoxicity, and microvascular stress conspire to impair the electron transport chain, the series of protein complexes that shuttles electrons to generate the proton gradient driving ATP synthesis. When electron transport becomes inefficient, electrons leak and combine with oxygen to form reactive oxygen species at rates that overwhelm cellular antioxidant defenses. The resulting oxidative attack damages mitochondrial DNA, producing markers such as 8-hydroxy-2′-deoxyguanosine, and oxidizes membrane lipids, generating aldehydes like 4-hydroxynonenal and malondialdehyde. Calcium handling deteriorates in parallel: excess cytosolic calcium floods the mitochondrial matrix through the mitochondrial calcium uniporter, and sustained stress triggers opening of the mitochondrial permeability transition pore, a catastrophic event that collapses the proton gradient and can commit the cell to death.

Beyond energy failure, the review emphasizes that mitochondria in neurons are dynamic organelles that must be continuously maintained, moved, and recycled. In healthy axons, a balance between fission and fusion—orchestrated by proteins such as dynamin-related protein 1, mitofusins, and optic atrophy 1—keeps the mitochondrial network functional. Diabetes disrupts this balance, tilting it toward excessive fragmentation. At the same time, the molecular motors that transport fresh mitochondria along microtubules to distal axon terminals falter, starving the nerve periphery of ATP exactly where it is needed most. Mitophagy, the quality-control process that identifies and digests damaged mitochondria via the PINK1–Parkin pathway and receptors such as optineurin and nuclear dot protein 52, becomes defective, allowing dysfunctional organelles to accumulate. Contacts between mitochondria and the endoplasmic reticulum, formed at mitochondria-associated ER membranes, also become abnormal, disturbing calcium transfer and lipid exchange between the two organelles.

One of the most striking sections of the review connects mitochondrial collapse to a newly recognized executioner of axons: the protein SARM1. When levels of the metabolic cofactor NAD+ fall—a direct consequence of mitochondrial dysfunction—SARM1 switches on and degrades remaining NAD+, triggering a self-destructive program that dismantles the axon from within. This places bioenergetic failure and axonal degeneration on a single mechanistic continuum. The authors also describe how damaged mitochondria release danger signals that activate the NLRP3 inflammasome, driving maturation of the inflammatory cytokines interleukin-1 beta and interleukin-18, and how mitochondrial DNA escaping into the cytoplasm engages the cGAS–STING pathway, provoking type I interferon responses. Together, these pathways convert intracellular energy failure into neuroinflammation, glial dysfunction, pain sensitization, and ultimately cell death.

A key insight of the review is that mitochondrial mechanisms appear to be shared across the different faces of diabetic neuropathy, even though the dominant cell types and clinical endpoints differ. In painful diabetic peripheral neuropathy, mitochondrial stress in sensory neurons and satellite glial cells of the dorsal root ganglion contributes to the hypersensitivity that characterizes chronic pain. In painless disease, the same bioenergetic collapse drives silent distal axonal loss and insensate feet at risk of ulceration. Corneal small-fibre neuropathy, increasingly assessed non-invasively with corneal confocal microscopy, reflects similar small-fibre mitochondrial injury, while cardiovascular autonomic neuropathy involves mitochondrial failure in autonomic neurons. Even diabetes-related injury in the central nervous system shows overlapping mitochondrial signatures, suggesting a unifying framework for what has historically been treated as a collection of separate syndromes.

The translational implications are where the review becomes most provocative. The authors survey a wide range of metabolism-oriented interventions currently under investigation. Exercise and dietary strategies can improve mitochondrial biogenesis through the AMPK–PGC-1 alpha axis and enhance insulin sensitivity. Metabolic regulators aim to redirect excess substrate away from overloaded electron transport chains. SARM1 inhibitors represent an emerging class designed to block the axon-destruction pathway directly, while calcium-pathway targeting seeks to prevent permeability transition pore opening and excitotoxic calcium overload. Mitophagy modulation aims to restore quality control, and mitochondria-directed antioxidants such as MitoQ and MitoTEMPO are engineered to accumulate inside mitochondria, where generic antioxidants like alpha-lipoic acid penetrate poorly. The authors also discuss traditional Chinese medicine and natural products, which contain compounds with mitochondrial-protective activities, though they stress that these require rigorous mechanistic and clinical validation.

Despite this wealth of mechanisms, the review is notably sober about the state of clinical evidence. The authors conclude that while target engagement has been demonstrated in experimental systems—cells, animal models, and early human biomarker studies—human validation remains insufficient. Tissue exposure data for many candidate drugs are lacking, structural nerve endpoints such as intraepidermal nerve fibre density and corneal nerve measures are inconsistently incorporated into trials, and high-quality disease-modifying trials are scarce. The narrative review format also carries limitations: the authors explicitly note that no formal risk-of-bias tool or GRADE assessment was applied, instead distinguishing human, animal, and cellular evidence narratively. The search drew on PubMed from database inception to 1 August 2026, supplemented by backward reference screening, prioritizing English-language mechanistic and translational studies.

Perhaps the most important message for patients and clinicians is a reframing of what treatment should aim for. Current management of diabetic neuropathy is largely symptomatic—pain relievers for discomfort and glycaemic control to slow progression—but does not repair damaged nerves. The review argues that the most actionable translational path is not symptomatic antioxidant use alone, which has repeatedly produced disappointing trial results, but biomarker-guided, mechanism-stratified trials. In practice, this would mean measuring mitochondrial targets in accessible tissues, stratifying patients by the dominant mechanism driving their disease, and connecting mitochondrial target modulation with small-fibre structure, nerve function, safety, and patient-centred outcomes such as pain, balance, and quality of life.

Mitochondrial dysfunction, the authors conclude, functions as a core pathogenic hub rather than the sole cause of diabetic neuropathy—a convergence point where substrate overload, redox imbalance, calcium stress, organelle quality-control failure, inflammatory signalling, and axonal degeneration meet. As diabetes rates continue to climb worldwide, and with no approved disease-modifying therapy for diabetic neuropathy, the review’s framework offers researchers a map of where to intervene next. Whether SARM1 inhibitors, mitophagy enhancers, or targeted mitochondrial antioxidants can finally change the trajectory of this devastating complication will depend on the rigorous, biomarker-driven human trials the authors say are urgently needed.

Subject of Research: Mitochondrial dysfunction as a pathogenic hub in diabetic neuropathy and its therapeutic implications

Article Title: Mitochondrial dysfunction in diabetic neuropathy: a core pathogenic hub and therapeutic implications

Article References: Wu, X., Li, X., Lou, N., Zhuang, X., & Chen, S. (2026). Mitochondrial dysfunction in diabetic neuropathy: a core pathogenic hub and therapeutic implications. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09015-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09015-y

Keywords: diabetic neuropathy, mitochondrial dysfunction, oxidative stress, mitophagy, SARM1, neuroinflammation, NLRP3 inflammasome, cGAS-STING, axonal degeneration, diabetic peripheral neuropathy, mitochondria-targeted antioxidants, Journal of Translational Medicine

To understand why MitoQ has generated such excitement, it helps to revisit the free radical theory of aging. Mitochondria consume roughly 90 percent of a cell’s molecular oxygen through the electron transport chain (ETC), a series of five protein complexes embedded in the inner mitochondrial membrane that converts energy from nutrients into ATP. During this process, electrons inevitably leak, mainly at complexes I and III, reducing oxygen to superoxide. Superoxide is converted by superoxide dismutase into hydrogen peroxide and, under some conditions, into the even more destructive hydroxyl radical. In youth, these reactive oxygen species (ROS) serve as controlled signaling molecules that help cells adapt. With age, however, the balance collapses: ROS damage the ETC enzymes, peroxidize cardiolipin—a phospholipid essential for stabilizing respiratory complex assembly—and mutate mitochondrial DNA, impairing the expression of mitochondrially encoded respiratory subunits. The result is a feed-forward cycle in which ROS-induced ETC dysfunction amplifies further ROS production, reducing ATP synthesis, dissipating membrane potential, and accelerating tissue deterioration.

The consequences extend far beyond energy production. Oxidative damage activates the p53/p21 pathway, driving cells into senescence, a largely irreversible state of cell cycle arrest in which cells remain metabolically active and secrete proinflammatory molecules—the senescence-associated secretory phenotype. Mitochondria-derived ROS also primes the NLRP3 inflammasome, a cytosolic multiprotein complex whose activation, through the TLR/MyD88/NF-κB pathway, triggers caspase-1 maturation of interleukin-1β and IL-18 and gasdermin D-mediated pyroptotic cell death. This links mitochondrial dysfunction directly to inflammaging, the chronic low-grade inflammation that accelerates cardiovascular disease, osteoporosis, type 2 diabetes, sarcopenia, and neurodegenerative disorders. Aging mitochondria also lose their fusion–fission balance: sedentary older adults show reduced OPA1 expression linked to sarcopenia, while the protease OMA1 cleaves fusion-active long OPA1 into inactive fragments, destabilizing cristae integrity. Calcium handling deteriorates in parallel, as excessive ROS oxidizes redox-sensitive residues in the IP3 receptor, VDAC, and the mitochondrial calcium uniporter, promoting permeability transition pore opening and further collapse of membrane potential.

Conventional antioxidants have largely failed to break this cycle. Clinical trials of vitamins E and C have shown inconsistent or limited benefits, and the review explains why: most small-molecule antioxidants distribute broadly throughout the body, and only a tiny fraction ever reaches mitochondria. MitoQ was designed to solve this delivery problem. It consists of a ubiquinone moiety—the antioxidant core of coenzyme Q10—covalently linked through an alkyl chain to a lipophilic triphenylphosphonium (TPP+) cation. The positively charged TPP+ group exploits the negative membrane potential across the inner mitochondrial membrane, concentrating roughly tenfold within cells and up to 1000-fold within mitochondria. Once inside, complex II reduces the ubiquinone to ubiquinol, which scavenges ROS before being oxidized back to ubiquinone—a redox cycle that allows continuous recycling and retention within the mitochondrial matrix. Crucially, the authors emphasize that MitoQ should not be considered simply a superior form of CoQ10: conjugation with TPP+ fundamentally alters its behavior, preventing it from acting as a physiological electron carrier and instead making it a targeted modulator of the local mitochondrial redox environment.

The strongest evidence for MitoQ lies in vascular aging. The endothelium maintains vascular homeostasis by producing nitric oxide through endothelial nitric oxide synthase, but aging reduces NO bioavailability because mitochondria-derived superoxide combines with NO to form peroxynitrite, and superoxide also uncouples eNOS by oxidizing its cofactor tetrahydrobiopterin. In aged mice, both acute and four-week MitoQ treatment restored endothelium-dependent dilation of the carotid artery by improving NO bioavailability, reducing nitrotyrosine expression, and suppressing rotenone-induced mitochondrial superoxide. MitoQ also reduced p66Shc, a signaling protein that regulates mitochondrial ROS and NADPH oxidase activity, and upregulated cytochrome c oxidase subunit IV, hinting at enhanced mitochondrial biogenesis. Chronic MitoQ administration in aged mice preserved elastin expression and reduced arterial stiffness. Human evidence is accumulating too: incubating isolated skeletal muscle feed arteries from older adults with MitoQ improved endothelium-dependent dilation, single doses enhanced flow-mediated dilation in middle-aged and postmenopausal women, and a six-week trial in older adults reduced circulating oxidized LDL—a molecule closely tied to vascular dysfunction.

MitoQ’s reach extends to heart failure, a leading cause of hospitalization in older adults. In a mouse model of pressure overload induced by ascending aortic constriction, one week of MitoQ treatment improved fractional shortening and ejection fraction and normalized left ventricular dimensions. Mechanistically, MitoQ normalized the redox-sensitive Plscr4–miR-214 axis, preserving expression of the fusion protein MFN2 and thereby maintaining mitochondrial network integrity and membrane potential, while enhancing mitochondria–sarcoplasmic reticulum coupling. In a rat model of transverse aortic constriction, fourteen weeks of MitoQ improved mitochondrial bioenergetics, normalized elevated hydrogen peroxide, enhanced calcium retention capacity, and attenuated permeability transition pore opening. Although established systolic dysfunction was not fully reversed, MitoQ reduced right ventricular hypertrophy and lung congestion, suggesting it may act as a disease-modifying strategy that limits progression rather than a cure.

The brain tells a similarly encouraging story. Mitochondrial dysfunction is a common feature of Alzheimer’s, Parkinson’s, and Huntington’s diseases, and peroxynitrite—one of the most reactive of the ROS and reactive nitrogen species—leaves behind 3-nitrotyrosine markers that are prominent in neurodegenerative pathology. Five weeks of MitoQ supplementation in aged rats reduced protein and lipid oxidation in the brain and restored impaired complex I and IV activity, consistent with improved membrane potential and ATP production. In aged mice, MitoQ alleviated deterioration in spatial and object recognition memory by restoring ATP production in synaptic mitochondria, and in transgenic Alzheimer’s mice it extended lifespan. These findings position mitochondrial ROS scavenging as a plausible approach to slowing cognitive decline, though the authors note that direct evidence for MitoQ modulating NLRP3 activation in aging-relevant brain tissue is still lacking.

Skeletal muscle, by contrast, has produced the review’s most sobering data. Sarcopenia—the progressive loss of muscle mass and strength—is closely tied to ROS accumulation in high oxygen-demand tissue, yet MitoQ’s record here is mixed. Fifteen weeks of 100 µM MitoQ failed to reduce oxidative damage or rescue muscle mass and function in roughly 28-month-old mice, whereas a higher dose of 250 µM for just four weeks reduced mitochondrial ROS and inflammation and enhanced physical performance in 27-month-old mice. In humans, six weeks of 20 mg/day reduced mitochondrial hydrogen peroxide emission in middle-aged men without changing respiratory capacity or mitochondrial content, and a twelve-week trial in older adults reduced hydrogen peroxide emission but left respiration, ADP sensitivity, and exercise-induced gene expression unchanged. Notably, a subgroup analysis found that only participants over 70 showed increased peak leg extension power and grip strength, hinting that baseline aging severity may determine who benefits. The authors suggest dosage, treatment duration, metabolic status, and baseline mitochondrial function all likely shape tissue-specific responses.

The review also ventures into less expected territory: lower urinary tract symptoms, which affect up to half of older adults and share biological pathways with aging and metabolic syndrome. Inflammation and oxidative stress damage detrusor myocytes, urothelium, vasculature, and bladder innervation, and the NLRP3 inflammasome is upregulated in aged urothelial cells, driving fibrosis and detrusor dysfunction. Because current pharmacologic treatments for these symptoms are only modestly effective and poorly tolerated in older patients, the authors propose MitoQ—capable of scavenging mitochondrial ROS, inhibiting NLRP3, promoting mitophagy, and improving endothelial NO availability—as a candidate therapy. A pilot feasibility study testing 40 mg/day MitoQ versus placebo on urinary urgency in women aged 50 and older with metabolic syndrome is already registered, marking one of the first attempts to test a mitochondria-targeted antioxidant against a geriatric syndrome beyond the cardiovascular system.

Where does this leave the field? MitoQ is among the most translationally advanced mitochondria-targeted antioxidants, with demonstrated oral bioavailability, human trial data, and commercial availability, while compounds such as MitoTEMPO and SkQ1 remain largely experimental tools. A systematic review and meta-analysis focused on oxidative stress biomarkers supports MitoQ’s potential to mitigate age-associated oxidative stress. Yet the authors are careful about the limits: current evidence does not show that MitoQ directly restores other hallmarks of mitochondrial aging, including altered dynamics, disrupted calcium homeostasis, or impaired quality control, and questions of long-term safety, cost-effectiveness, and interindividual variability in mitochondrial accumulation remain open. Future work, they argue, should systematically test MitoQ against mitochondrial dynamics, calcium handling, and NLRP3 activation in aging tissues, and design clinical trials to define optimal dosing, duration, and the populations most likely to benefit. If those trials succeed, the humble ubiquinone molecule hitched to a charged phosphorus group could become one of the first practical tools for extending not just lifespan, but health span.

Subject of Research: Therapeutic potential of the mitochondria-targeted antioxidant MitoQ in age-related physiological dysfunction

Article Title: Therapeutic potential of MitoQ, a mitochondria-targeted antioxidant, in age-related physiological dysfunction

Article References: Kim, S., Noh, S. G., Ji, M., Chen, K., Kuchel, G. A., Al-Naggar, I. M., & Kwon, O. S. (2026). Therapeutic potential of MitoQ, a mitochondria-targeted antioxidant, in age-related physiological dysfunction. GeroScience. https://doi.org/10.1007/s11357-026-02515-1

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02515-1

Keywords: MitoQ, mitochondria, antioxidant, aging, reactive oxygen species, oxidative stress, cardiovascular aging, neurodegeneration, sarcopenia, NLRP3 inflammasome, inflammaging, GeroScience